Hi friend,
It’s been an interesting fortnight in mental health.
Flagship Pioneering, Outro, Allswell, Brellium and Rogers all raised funds. Zocdoc acquired Sohar, Headspace issued layoffs following the Sword acquisition, and Sword debuted their own frontier AI model.
The FDA has been active, granting approvals to Teva (for Weltruza) and to Click (for Motivista). In the UK, the Fonagy report was published, offering important insights on ADHD and Autism in the country. We also saw new data from the CDC, Gallup and the UK Government on the emotional and psychological state of different populations — all tell an interesting, yet complicated story.
More research was published on AI performance (including new data from Slingshot) as well as insights into TMS performance for late-life TRD and the association of GLP-1 usage with hospitalisation rates among schizophrenia patients with diabetes.
Lots to cover, so let’s get into it!
